EXEL

42.70

0.56% -0.24

Handel nachbörslich: 42.70

Exelixis Inc (EXEL)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt EXEL? Forum Prognose

Schlusskurs vom Vortag:

$42.94

Offen:

$42.83

24-Stunden-Volumen:

2.56M

Relative Volume:

0.99

Marktkapitalisierung:

$11.09B

Einnahmen:

$2.29B

Nettoeinkommen (Verlust:

$677.90M

KGV:

17.98

EPS:

2.3753

Netto-Cashflow:

$779.77M

1W Leistung:

+0.78%

1M Leistung:

-3.09%

6M Leistung:

+12.52%

1J Leistung:

+30.18%

1-Tages-Spanne:

$42.35

$43.52

1-Wochen-Bereich:

$40.92

$44.28

52-Wochen-Spanne:

$32.38

$49.62

Exelixis Inc Stock (EXEL) Company Profile

Firmenname

Exelixis Inc

Sektor

Healthcare (1112)

Branche

Biotechnology (621)

Telefon

(650) 837-7000

Adresse

1851 HARBOR BAY PARKWAY, ALAMEDA, CA

Mitarbeiter

1,147

Twitter

@exelixisinc

Nächster Verdiensttermin

2025-07-28

Neueste SEC-Einreichungen

EXEL's Discussions on Twitter

Compare EXEL vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
EXEL Exelixis Inc	42.70	11.15B	2.29B	677.90M	779.77M	2.3753
VRTX Vertex Pharmaceuticals Inc	465.02	117.03B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	783.65	82.35B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	833.54	51.64B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	308.48	42.58B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	346.42	38.87B	4.98B	69.60M	525.67M	0.5198

Exelixis Inc Stock (EXEL) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-08	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2026-01-05	Herabstufung	BofA Securities	Neutral → Underperform
2025-11-18	Eingeleitet	Wolfe Research	Peer Perform
2025-11-03	Herabstufung	Guggenheim	Buy → Neutral
2025-10-21	Hochstufung	Leerink Partners	Market Perform → Outperform
2025-09-19	Fortgesetzt	Barclays	Equal Weight
2025-09-17	Fortgesetzt	Barclays	Equal Weight
2025-09-17	Eingeleitet	Goldman	Buy
2025-07-08	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2025-06-24	Hochstufung	Stephens	Equal-Weight → Overweight
2025-02-24	Herabstufung	Wells Fargo	Overweight → Equal Weight
2025-01-27	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2025-01-24	Herabstufung	Oppenheimer	Outperform → Perform
2024-12-20	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2024-12-17	Herabstufung	BofA Securities	Buy → Neutral
2024-10-16	Bestätigt	RBC Capital Mkts	Outperform
2024-09-19	Eingeleitet	UBS	Neutral
2024-04-11	Herabstufung	Barclays	Overweight → Equal Weight
2023-12-19	Eingeleitet	BTIG Research	Buy
2023-12-15	Eingeleitet	Citigroup	Buy
2023-09-26	Eingeleitet	H.C. Wainwright	Buy
2023-08-22	Bestätigt	Oppenheimer	Outperform
2023-08-08	Eingeleitet	SVB Securities	Market Perform
2023-07-11	Fortgesetzt	Morgan Stanley	Equal-Weight
2023-05-10	Fortgesetzt	Piper Sandler	Overweight
2023-03-09	Eingeleitet	Wells Fargo	Overweight
2023-01-26	Eingeleitet	Credit Suisse	Outperform
2022-10-18	Eingeleitet	JMP Securities	Mkt Outperform
2022-06-24	Eingeleitet	BMO Capital Markets	Outperform
2021-11-19	Eingeleitet	Piper Sandler	Overweight
2021-11-03	Fortgesetzt	Jefferies	Buy
2021-10-07	Eingeleitet	Jefferies	Buy
2021-08-06	Bestätigt	H.C. Wainwright	Buy
2021-06-15	Eingeleitet	H.C. Wainwright	Buy
2021-05-18	Fortgesetzt	Goldman	Sell
2021-03-31	Eingeleitet	Credit Suisse	Outperform
2021-03-12	Eingeleitet	Wolfe Research	Outperform
2020-03-04	Eingeleitet	Barclays	Overweight
2020-01-13	Eingeleitet	SunTrust	Buy
2019-11-13	Eingeleitet	BofA/Merrill	Buy
2019-03-18	Hochstufung	Morgan Stanley	Underweight → Equal-Weight
2018-09-17	Eingeleitet	Goldman	Neutral
2018-09-10	Eingeleitet	Morgan Stanley	Underweight
2018-05-11	Bestätigt	Needham	Buy
2017-10-17	Bestätigt	Needham	Buy
2017-10-17	Bestätigt	RBC Capital Mkts	Outperform
2017-10-16	Bestätigt	SunTrust	Buy
2017-09-22	Herabstufung	Leerink Partners	Outperform → Mkt Perform
2017-09-15	Eingeleitet	RBC Capital Mkts	Outperform
2017-09-12	Bestätigt	Needham	Buy
2017-07-14	Eingeleitet	SunTrust	Buy
2017-03-31	Eingeleitet	Needham	Buy
2017-03-16	Eingeleitet	Oppenheimer	Perform
2017-02-28	Herabstufung	Stifel	Buy → Hold
2016-11-03	Eingeleitet	Deutsche Bank	Buy
2016-10-10	Hochstufung	Piper Jaffray	Neutral → Overweight
2016-09-15	Bestätigt	Stifel	Buy

Alle ansehen

Exelixis Inc Aktie (EXEL) Neueste Nachrichten

05:56 AM

Exelixis (EXEL) Q4 2025 Earnings Call Transcript - AOL.com

05:56 AM

04:20 AM

Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL) and OrganiGram Holdings (OGI) - The Globe and Mail

04:20 AM

04:10 AM

Exelixis stock price target raised to $54 from $52 at H.C. Wainwright By Investing.com - Investing.com India

08:14 AM

08:01 AM

Exelixis stock price target raised to $54 from $52 at H.C. Wainwright - Investing.com

08:01 AM

07:44 AM

EXEL: HC Wainwright & Co. Raises Price Target, Maintains Buy Rat - GuruFocus

07:44 AM

07:01 AM

A Glimpse Into The Expert Outlook On Exelixis Through 10 Analysts - Benzinga

07:01 AM

Feb 11, 2026

Exelixis (NASDAQ:EXEL) Price Target Raised to $46.00 - MarketBeat

Feb 11, 2026

EXEL: Stifel Raises Price Target to $44 and Maintains Hold Ratin - GuruFocus

Feb 11, 2026

Exelixis (NASDAQ:EXEL) Price Target Raised to $35.00 - MarketBeat

Feb 11, 2026

Citizens maintains Exelixis stock rating on promising cancer treatment data By Investing.com - Investing.com Canada

Feb 11, 2026

EXEL Q4 Earnings and Revenues Beat, Colorectal Cancer Drug in Focus - Yahoo Finance UK

Feb 11, 2026

RBC Raises Price Target on Exelixis to $46 From $45, Keeps Sector Perform Rating - marketscreener.com

Feb 11, 2026

Citizens maintains Exelixis stock rating on promising cancer treatment data - Investing.com

Feb 11, 2026

Exelixis, Inc. (NASDAQ:EXEL) Q4 2025 Earnings Call Transcript - Insider Monkey

Feb 11, 2026

Essex Investment Management Co. LLC Raises Stock Position in Exelixis, Inc. $EXEL - MarketBeat

Feb 11, 2026

Decoding Exelixis Inc (EXEL): A Strategic SWOT Insight - GuruFocus

Feb 11, 2026